These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37270453)

  • 1. Real-World Effects of Second-Generation Versus Earlier Intermediate/Basal Insulin Analogues on Rates of Hypoglycemia in Adults with Type 1 and 2 Diabetes (iNPHORM, US).
    Black JE; Harris SB; Ryan BL; Zou G; Ratzki-Leewing A
    Diabetes Ther; 2023 Aug; 14(8):1299-1317. PubMed ID: 37270453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Real-world Hypoglycemia Risk in American Adults With Type 1 or 2 Diabetes Mellitus Prescribed Insulin and/or Secretagogues: Protocol for a Prospective, 12-Wave Internet-Based Panel Survey With Email Support (the iNPHORM [Investigating Novel Predictions of Hypoglycemia Occurrence Using Real-world Models] Study).
    Ratzki-Leewing A; Ryan BL; Zou G; Webster-Bogaert S; Black JE; Stirling K; Timcevska K; Khan N; Buchenberger JD; Harris SB
    JMIR Res Protoc; 2022 Feb; 11(2):e33726. PubMed ID: 35025756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review.
    Cheng AYY; Wong J; Freemantle N; Acharya SH; Ekinci E
    Diabetes Ther; 2020 Nov; 11(11):2555-2593. PubMed ID: 32975710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe (level 3) hypoglycaemia occurrence in a real-world cohort of adults with type 1 or 2 diabetes mellitus (iNPHORM, United States).
    Ratzki-Leewing A; Black JE; Kahkoska AR; Ryan BL; Zou G; Klar N; Timcevska K; Harris SB
    Diabetes Obes Metab; 2023 Dec; 25(12):3736-3747. PubMed ID: 37700692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.
    Pettus J; Roussel R; Liz Zhou F; Bosnyak Z; Westerbacka J; Berria R; Jimenez J; Eliasson B; Hramiak I; Bailey T; Meneghini L
    Diabetes Ther; 2019 Apr; 10(2):617-633. PubMed ID: 30767173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
    Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
    [No Abstract]   [Full Text] [Related]  

  • 9. Development and validation of a real-world model to predict 1-year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States).
    Ratzki-Leewing AA; Black JE; Ryan BL; Zou G; Klar N; Webster-Bogaert S; Timcevska K; Harris SB
    Diabetes Obes Metab; 2023 Oct; 25(10):2910-2927. PubMed ID: 37409569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Tolerability of Insulin Degludec Versus Other Long-acting Basal Insulin Analogues in the Treatment of Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    Dong ZY; Feng JH; Zhang JF
    Clin Ther; 2022 Nov; 44(11):1520-1533. PubMed ID: 36763996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
    Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.
    Elliott L; Fidler C; Ditchfield A; Stissing T
    Diabetes Ther; 2016 Mar; 7(1):45-60. PubMed ID: 26886441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
    Blonde L; Bailey T; Sullivan SD; Freemantle N
    Diabetes Obes Metab; 2021 Aug; 23(8):1713-1721. PubMed ID: 33881797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study.
    Fadini GP; Feher M; Hansen TK; de Valk HW; Koefoed MM; Wolden M; Zimmermann E; Jendle J
    J Clin Endocrinol Metab; 2019 Dec; 104(12):5977-5990. PubMed ID: 31397845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Basal insulin glargine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice - safety and efficacy in basal bolus regimen)].
    Zďarská DJ; Brož J; Křivská B; Rušavý Z; Kvapil M
    Vnitr Lek; 2014 Sep; 60(9):712-9. PubMed ID: 25294758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.
    Vora J; Christensen T; Rana A; Bain SC
    Diabetes Ther; 2014 Dec; 5(2):435-46. PubMed ID: 25081590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
    Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Incidence and Risk Factors for Daytime and Nocturnal Non-Severe Hypoglycemia in Adults With Type 2 Diabetes Mellitus on Insulin and/or Secretagogues (InHypo-DM Study, Canada).
    Au NH; Ratzki-Leewing A; Zou G; Ryan BL; Webster-Bogaert S; Reichert SM; Brown JB; Harris SB
    Can J Diabetes; 2022 Mar; 46(2):196-203.e2. PubMed ID: 35288040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.